Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease (IBD) and other immune-mediated conditions. The company engineers extended half-life monoclonal antibodies and rational therapeutic combinations designed to improve dosing convenience and patient outcomes. Its core pipeline targets key biological pathways including α4β7, TL1A, and IL-23. Lead candidates include SPY001, an anti-α4β7 antibody, and SPY002 and SPY072, which target TL1A for the treatment of IBD and rheumatic diseases. Spyre is also advancing combination therapies such as SPY120 and SPY130 to address unmet needs in precision immunology. The company operates primarily out of Waltham, Massachusetts, and assumed its current form following a reverse merger with Aeglea BioTherapeutics in 2023.
